Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q1 2020 Earnings Presentation
17 slides from Bonesupport Holding Ab's earnings presentation, May 8, 2020
Slide 1: BONESUPPORT Q1(20)
BONESUPPORT Q1(20) May 8" 2020 Emil Billback, CEO Hakan Johansson CFO
Slide 2: Disclaimer
§ BONESUPPORT DISCLAIMER ‘This presentation, which indudes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed orstatements made at, orin connection with, such presentation (the “Presentation”), relates to BONESU
Slide 3: Financial highlights
Financial highlights r~Y * Q1 (20) net sales SEK43m, growth +32% * EU & ROW Q1(20): +4% Y/Y to SEK22m * CERAMENT G & V Q1(20): +2% * North America Q1(20): +84% * QI gross margin: 89% Operational highlights > * Positive traction in new sales territories ~<a . + Appointment of new distribution partner
Slide 4: Covid-19 – Impact, measures and outlook
< BONESUPPORT Covid-19 — Impact, measures and outlook Elective surgeries down, acute surgeries influenced to a lesser extent * Could delay recruitment of new customers * Cost reductions - work time reductions and voluntary salary reductions * Lower sales H1 2020, difficult to assess full year * No g
Slide 5: Q1 2020 represented a new all-time-high, despite influence from the Corona pandemic
Q1 2020 represented a new all-time-high, despite influence from the Corona pandemic LTM Quarterly Sales per Segment 180 * Q1 2020 represented a 160 140 132 166 155 new all-time-high, despite = 128 48 132 influence from the Covid- ua 119 19 pandemic 107 98 a 101 97 98 * North America grew with an & 1
Slide 6: EUROW – Covid-19 influence. Revitalizing indirect markets
< BONESUPPORT EUROW - Covid -19 influence. Revitalizing indirect markets Q1 2020 * Sales of SEK22m, growth of 4% + Antibioticeluting products growth of 2% * Direct markets represent 86% of sales Highlights * Early in Q1 appointment of new distributor partners in Italy and France — short term disrupt
Slide 7: North America – Accelerating CERAMENT G market entrance preparations
< BONESUPPORT North America — Accelerating CERAMENT G market entrance preparations Qi 2020 * Total sales of SEK21m, 84% growth vs Q1 2019 Progressing with registration of CERAMENTG * Breakthrough device designation * De Novo application submitted in April 2020 for CERAMENTG in bone infections (osteo
Slide 8: = a > a cc 1S) c oO iS as Ky = ——=— RES
= a > a cc 2 1S) c oO iS as Ky = ——=— RES * = CD enn z f \) ; a ae
Slide 9: Q1(20) net sales SEK43m – Good growth despite Covid-19 influence
< BONESUPPORT Q1(20) net sales SEK43m — Good growth despite Covid-19 influence (sEKm) Net Sales per quarter 432% 50.0 46.2 175.0 Net Sales 4 37.3 si = 40.0 140.0 32.8 300 — = 105.0 20.0 70.0 10.0 35.0 0.0 0.0 q1iy Qz19 Qs-19 aa-1y Q1-20 mum Net Sales per quarter —=—=LTM
Slide 10: North America
North America feecy Tan ar TF 7520) 2015 Net Sales 21.2 11.5 Gross profit 19.7. 10.3 Contribution -12.2 -15.7 (stkm) Net Sales per quarter 23.3 18.9 14.8 | Q2-19 Q3-19 4-19 +84% Net Sales Qi < BONESUPPORT 10
Slide 11: EUROW
EUROW pt isl 2018 Net Sales 22.2 21.3 4% Gross profit 18.9 17.9 Net Sales Contribution 3.9 09 Ql (SEKm) Net Sales per quarter 11
Slide 12: Stable performance in Q1 despite influence from Covid-19
Stable performance in Q1 despite influence from Covid-19 lKeyFigures | ozo} ong ng sekm Tc i ef] Si] Sa] Si] Net Sales 43.4 46.2 39.1 37.3 32.8 23.4 14.2 28.2 Gross Margin (%) 88.7 88.9 87.7 86.5 85.9 85.0 81.8 87.4 Operating Loss -29.2 -38.6 -32.7 47.8 -39.0 -45.0 -58.4 -37.8 Cash at period end 680
Slide 13: Early impact of cost reductions
< BONESUPPORT Early impact of cost reductions lKeyFigures | ozo) ong org sem a i igs] ey Sci | a | is |g | Selling expenses (less Aas 35.0 41.3 33.5 47.9 37.3 37.7 35.1 31.8 commissions) Sales Commissions 71 8.0 6.0 48 3.5 11 - - Research and Development 15.8 18.5 174 16.0 169 176 16.4 17.2 expenses
Slide 14: Driving Value Creation
> &0 ov YY oO — o Nn v ~~ oO — ° a — ° O — is) a O Driving Value Creation Af aa _— ee: Bs PL i—#
Slide 15: Continued focus on strategy execution
Continued focus on strategy execution ad Cementing the platform for an accelerated growth journey — despite Covid-19-pandemic * Revitalising distributor markets * Leveraging the value from clinical and Health Economic evidence * Market introduction of CERAMENT G in the US - De Novo application — to
Slide 16: CERAMENT Value generating milestones
CERAMENT® Value generating milestones Q3 2020 CERAMENT® G Australia Launch May 20% Zimmer Q4 2021 CERAMENT® G Biomet ceases to sell CERAMENT PMA application 2019 2020 2022 2023 Q1 2019 SOLARIO. First Patient included H1 2020 FORTIFY patient inclusion complete 2022: SOLARIO Last Patient Data Q4 2019
Slide 17: Nir -ee
Nir -ee Gs ee —